

From: [REDACTED]
Sent: Friday 8 January 2021 16:21
To: [REDACTED]
Cc: [REDACTED]
Subject: Fwd: SUBJECT: CALL FOR TENDERS SANTE/2020/C3/087 – OFFER
Attachments: [REDACTED]

Categories: [REDACTED]

Dear [REDACTED],

Please see the following email with attachments as follow up to your recent request. We look forward to any updates.

Kind Regards,
[REDACTED]
Novavax, INC.
Get [Outlook for iOS](#)

From: [REDACTED]
Sent: Friday, January 8, 2021 10:12 AM
To: [REDACTED]
Cc: [REDACTED]
Subject: SUBJECT: CALL FOR TENDERS SANTE/2020/C3/087 – OFFER

Dear [REDACTED],

In response to the additional information you requested on 1-6-21, we are providing the following in hopes that it meets your needs:

1. Additional financial details

1. We submitted a clarifying question to you on 1/6 and are awaiting your response before sending this information

2a. Evidence regarding situations of exclusion described in (a), (c), (d), (f), (g) and (h) of Part I of Annex 6 to the Tender Specifications

1. [REDACTED]

2b. Evidence regarding situations of exclusion described in (b) of Part I of Annex 6 to the Tender Specifications:

2. [REDACTED]

1. [REDACTED]
2. [REDACTED]

Confidentiality Note

Please be advised that Novavax, Inc. (together with its subsidiaries "Novavax") is providing this proposal solely for the European Commission ("EC") to use in the call for tenders SANTE/2020/C3/087 - for the development, production, priority-purchasing options and supply of COVID-19 Vaccines for EU Member States (the "Project") and with the understanding that proposal contents will be treated as confidential. The information included in this proposal is confidential and/or private internal information of Novavax and its suppliers that is commercially sensitive and valuable. In accordance with the EC's procedures and relevant European Union law, we hereby request confidential treatment of all of the materials included in the proposal

Cheers,



22 Firstfield Road
Gaithersburg, MD 20878
Mobile: [REDACTED]
Email: [REDACTED]
www.novavax.com

From [REDACTED]
Sent: Wednesday, January 6, 2021 10:41 AM
To: [REDACTED]
Cc: [REDACTED]
Subject: RE: CALL FOR TENDERS SANTE/2020/C3/087 – OFFER



Dear [REDACTED],

After a first review of the documents submitted by Novavax Inc. it seems that we are missing the following elements:

1. Evidence regarding the financial and economic capacity F1 allowing the calculation of the survival ratio [REDACTED] as described in **section 3.2.2. of the Tender Specifications.**

2. Evidence regarding the exclusion criteria as described in the section **VI of the Declaration of Honor**. We acknowledge the receipt of the [REDACTED], however this document cannot be accepted as sufficient evidence. In consequence we would ask you to provide:

1. **As evidence regarding situations of exclusion described in (a), (c), (d), (f), (g) and (h) of Part I of Annex 6 to the Tender Specifications:** [REDACTED]

2. **As evidence regarding situations of exclusion described in (b) of Part I of Annex 6 to the Tender Specifications:** [REDACTED]

Please note that this is a first, general review of your submission, and we might come back to you with further requests following the assessment by the evaluation committee.

We remain at your disposal in case of any doubts or questions regarding the request.

Kind regards

[REDACTED]



European Commission
DG Health and Food Safety

[REDACTED]